Vesalius Research Center
Herestraat 49 box 912
B-3000 Leuven

phone +32 16 34 57 75
fax +32 16 34 59 90

Home arrow Valorization arrow Clinical Development
Clinical Development of VRC programs with the industry

Two preclinical projetcs of the VRC, anti-PlGF for the treatment of cancer and eye disease, and VEGF treatment for ALS, are currently being developed for clinical use together with biotech companies. Clinical trials for both programs are being planned and will likely start before the end of the year.

 
Thrombo.gif Thrombogenics
Development of anti-PlGF
for treatment of
cancer and eye disease
BIOinvent.gif BioInvent
Development of anti-PlGF
for treatment of
cancer and eye disease
NOVA.gif NeuroNova
Development of VEGF
treatment for ALS